The United States Patent and Trademark Office (USPTO) has issued patent US12582604B2 to BeiGene, Ltd. for a stable solid dispersion containing a specific B-RAF kinase dimer inhibitor (Compound 1) and a stabilizing polymer. The patent also covers methods for preparing this solid dispersion and its therapeutic uses, particularly for treating conditions related to B-RAF kinase activity. The filing date for this application was January 23, 2020, and the patent grant date is March 24, 2026.

This patent grant represents a new intellectual property asset for BeiGene, Ltd. in the area of oncology therapeutics. While not a regulatory rule imposing obligations on other entities, it signifies a novel composition and potential new treatment modality. Companies involved in B-RAF inhibitor research or development should be aware of this granted patent to ensure their activities do not infringe upon the claimed intellectual property. No immediate compliance actions are required for external parties, but it may influence future R&D strategies and licensing considerations.